Zobraziť v EDS

Development of a Decision Model to Estimate the Outcomes of Treatment Sequences in Advanced Melanoma

Uložené v:
Podrobná bibliografia
Názov: Development of a Decision Model to Estimate the Outcomes of Treatment Sequences in Advanced Melanoma
Autori: Saskia de Groot, Hedwig M. Blommestein, Brenda Leeneman, Carin A. Uyl-de Groot, John B. A. G. Haanen, Michel W. J. M. Wouters, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Willeke A. M. Blokx, Marye J. Boers-Sonderen, Alfons J. M. van den Eertwegh, Jan Willem B. de Groot, Geke A. P. Hospers, Ellen Kapiteijn, Olivier J. van Not, Astrid A. M. van der Veldt, Karijn P. M. Suijkerbuijk, Pieter H. M. van Baal
Prispievatelia: Pathologie Pathologen staf, Cancer, MS Medische Oncologie, Infection & Immunity
Zdroj: Med Decis Making
Medical Decision Making, 45, 3, pp. 302-317
Informácie o vydavateľovi: SAGE Publications, 2025.
Rok vydania: 2025
Predmety: Proto-Oncogene Proteins B-raf, Decision Support Techniques, COST-EFFECTIVENESS, SDG 3 - Good Health and Well-being, Original Research Articles, Proto-Oncogene Proteins B-raf/genetics, Journal Article, BRAF plus MEK inhibitors, METASTATIC MELANOMA, Humans, Melanoma/drug therapy, Skin Neoplasms/mortality, Medical Oncology - Radboud University Medical Center, Melanoma, treatment sequences, immunotherapies, Advanced melanoma, Prognosis, Markov Chains, Treatment Outcome, Mutation, SURVIVAL, Disease Progression, decision model, semi-Markov, REAL-WORLD
Popis: Background A decision model for patients with advanced melanoma to estimate outcomes of a wide range of treatment sequences is lacking. Objectives To develop a decision model for advanced melanoma to estimate outcomes of treatment sequences in clinical practice with the aim of supporting decision making. The article focuses on methodology and long-term health benefits. Methods A semi-Markov model with a lifetime horizon was developed. Transitions describing disease progression, time to next treatment, and mortality were estimated from real-world data (RWD) as a function of time since starting treatment or disease progression and patient characteristics. Transitions were estimated separately for melanoma with and without a BRAF mutation and for patients with favorable and intermediate prognostic factors. All transitions can be adjusted using relative effectiveness of treatments derived from a network meta-analysis of randomized controlled trials (RCTs). The duration of treatment effect can be adjusted to obtain outcomes under different assumptions. Results The model distinguishes 3 lines of systemic treatment for melanoma with a BRAF mutation and 2 lines of systemic treatment for melanoma without a BRAF mutation. Life expectancy ranged from 7.8 to 12.0 years in patients with favorable prognostic factors and from 5.1 to 8.7 years in patients with intermediate prognostic factors when treated with sequences consisting of targeted therapies and immunotherapies. Scenario analyses illustrate how estimates of life expectancy depend on the duration of treatment effect. Conclusion The model is flexible because it can accommodate different treatments and treatment sequences, and the duration of treatment effects and the transitions influenced by treatment can be adjusted. We show how using RWD and data from RCTs can harness advantages of both data sources, guiding the development of future decision models. Highlights The model is flexible because it can accommodate different treatments and treatment sequences, and the duration of treatment effects as well as the transitions that are influenced by treatment can be adjusted. The long-term health benefits of treatment sequences depend on the place of different therapies within a treatment sequence. Assumptions about the duration of relative treatment effects influence the estimates of long-term health benefits. We show how the use of real-world data and data from randomized controlled trials harness the advantages of both data sources, guiding the development of future decision models.
Druh dokumentu: Article
Other literature type
Popis súboru: application/pdf
Jazyk: English
ISSN: 1552-681X
0272-989X
DOI: 10.1177/0272989x251319338
Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39985400
https://hdl.handle.net/https://repository.ubn.ru.nl/handle/2066/317779
https://doi.org/10.1177/0272989X251319338
https://pure.eur.nl/en/publications/d251aa20-b9d9-4558-8a6d-1e3132efcf5f
https://doi.org/10.1177/0272989X251319338
https://research.rug.nl/en/publications/78b43b9d-b315-43b7-860a-00f5bf5a2ef7
https://hdl.handle.net/11370/78b43b9d-b315-43b7-860a-00f5bf5a2ef7
https://doi.org/10.1177/0272989X251319338
https://cris.maastrichtuniversity.nl/en/publications/dec7d975-1de4-4147-b028-58c982e4f704
https://doi.org/10.1177/0272989X251319338
https://dspace.library.uu.nl/handle/1874/461022
https://hdl.handle.net/2066/317779
https://repository.ubn.ru.nl//bitstream/handle/2066/317779/317779.pdf
Rights: CC BY
URL: https://journals.sagepub.com/page/policies/text-and-data-mining-license
URL: http://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 License (http://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (http://us.sagepub.com/en-us/nam/open-access-at-sage).
Prístupové číslo: edsair.doi.dedup.....6f71dc4ba3039165d5644c57bf0e5d3f
Databáza: OpenAIRE
FullText Text:
  Availability: 0
CustomLinks:
  – Url: https://explore.openaire.eu/search/publication?articleId=doi_dedup___%3A%3A6f71dc4ba3039165d5644c57bf0e5d3f
    Name: EDS - OpenAIRE (s4221598)
    Category: fullText
    Text: View record at OpenAIRE
  – Url: https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=EBSCO&SrcAuth=EBSCO&DestApp=WOS&ServiceName=TransferToWoS&DestLinkType=GeneralSearchSummary&Func=Links&author=de%20Groot%20S
    Name: ISI
    Category: fullText
    Text: Nájsť tento článok vo Web of Science
    Icon: https://imagesrvr.epnet.com/ls/20docs.gif
    MouseOverText: Nájsť tento článok vo Web of Science
Header DbId: edsair
DbLabel: OpenAIRE
An: edsair.doi.dedup.....6f71dc4ba3039165d5644c57bf0e5d3f
RelevancyScore: 1015
AccessLevel: 3
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 1014.74975585938
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Development of a Decision Model to Estimate the Outcomes of Treatment Sequences in Advanced Melanoma
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Saskia+de+Groot%22">Saskia de Groot</searchLink><br /><searchLink fieldCode="AR" term="%22Hedwig+M%2E+Blommestein%22">Hedwig M. Blommestein</searchLink><br /><searchLink fieldCode="AR" term="%22Brenda+Leeneman%22">Brenda Leeneman</searchLink><br /><searchLink fieldCode="AR" term="%22Carin+A%2E+Uyl-de+Groot%22">Carin A. Uyl-de Groot</searchLink><br /><searchLink fieldCode="AR" term="%22John+B%2E+A%2E+G%2E+Haanen%22">John B. A. G. Haanen</searchLink><br /><searchLink fieldCode="AR" term="%22Michel+W%2E+J%2E+M%2E+Wouters%22">Michel W. J. M. Wouters</searchLink><br /><searchLink fieldCode="AR" term="%22Maureen+J%2E+B%2E+Aarts%22">Maureen J. B. Aarts</searchLink><br /><searchLink fieldCode="AR" term="%22Franchette+W%2E+P%2E+J%2E+van+den+Berkmortel%22">Franchette W. P. J. van den Berkmortel</searchLink><br /><searchLink fieldCode="AR" term="%22Willeke+A%2E+M%2E+Blokx%22">Willeke A. M. Blokx</searchLink><br /><searchLink fieldCode="AR" term="%22Marye+J%2E+Boers-Sonderen%22">Marye J. Boers-Sonderen</searchLink><br /><searchLink fieldCode="AR" term="%22Alfons+J%2E+M%2E+van+den+Eertwegh%22">Alfons J. M. van den Eertwegh</searchLink><br /><searchLink fieldCode="AR" term="%22Jan+Willem+B%2E+de+Groot%22">Jan Willem B. de Groot</searchLink><br /><searchLink fieldCode="AR" term="%22Geke+A%2E+P%2E+Hospers%22">Geke A. P. Hospers</searchLink><br /><searchLink fieldCode="AR" term="%22Ellen+Kapiteijn%22">Ellen Kapiteijn</searchLink><br /><searchLink fieldCode="AR" term="%22Olivier+J%2E+van+Not%22">Olivier J. van Not</searchLink><br /><searchLink fieldCode="AR" term="%22Astrid+A%2E+M%2E+van+der+Veldt%22">Astrid A. M. van der Veldt</searchLink><br /><searchLink fieldCode="AR" term="%22Karijn+P%2E+M%2E+Suijkerbuijk%22">Karijn P. M. Suijkerbuijk</searchLink><br /><searchLink fieldCode="AR" term="%22Pieter+H%2E+M%2E+van+Baal%22">Pieter H. M. van Baal</searchLink>
– Name: Author
  Label: Contributors
  Group: Au
  Data: Pathologie Pathologen staf<br />Cancer<br />MS Medische Oncologie<br />Infection & Immunity
– Name: TitleSource
  Label: Source
  Group: Src
  Data: Med Decis Making<br />Medical Decision Making, 45, 3, pp. 302-317
– Name: Publisher
  Label: Publisher Information
  Group: PubInfo
  Data: SAGE Publications, 2025.
– Name: DatePubCY
  Label: Publication Year
  Group: Date
  Data: 2025
– Name: Subject
  Label: Subject Terms
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Proto-Oncogene+Proteins+B-raf%22">Proto-Oncogene Proteins B-raf</searchLink><br /><searchLink fieldCode="DE" term="%22Decision+Support+Techniques%22">Decision Support Techniques</searchLink><br /><searchLink fieldCode="DE" term="%22COST-EFFECTIVENESS%22">COST-EFFECTIVENESS</searchLink><br /><searchLink fieldCode="DE" term="%22SDG+3+-+Good+Health+and+Well-being%22">SDG 3 - Good Health and Well-being</searchLink><br /><searchLink fieldCode="DE" term="%22Original+Research+Articles%22">Original Research Articles</searchLink><br /><searchLink fieldCode="DE" term="%22Proto-Oncogene+Proteins+B-raf%2Fgenetics%22">Proto-Oncogene Proteins B-raf/genetics</searchLink><br /><searchLink fieldCode="DE" term="%22Journal+Article%22">Journal Article</searchLink><br /><searchLink fieldCode="DE" term="%22BRAF+plus+MEK+inhibitors%22">BRAF plus MEK inhibitors</searchLink><br /><searchLink fieldCode="DE" term="%22METASTATIC+MELANOMA%22">METASTATIC MELANOMA</searchLink><br /><searchLink fieldCode="DE" term="%22Humans%22">Humans</searchLink><br /><searchLink fieldCode="DE" term="%22Melanoma%2Fdrug+therapy%22">Melanoma/drug therapy</searchLink><br /><searchLink fieldCode="DE" term="%22Skin+Neoplasms%2Fmortality%22">Skin Neoplasms/mortality</searchLink><br /><searchLink fieldCode="DE" term="%22Medical+Oncology+-+Radboud+University+Medical+Center%22">Medical Oncology - Radboud University Medical Center</searchLink><br /><searchLink fieldCode="DE" term="%22Melanoma%22">Melanoma</searchLink><br /><searchLink fieldCode="DE" term="%22treatment+sequences%22">treatment sequences</searchLink><br /><searchLink fieldCode="DE" term="%22immunotherapies%22">immunotherapies</searchLink><br /><searchLink fieldCode="DE" term="%22Advanced+melanoma%22">Advanced melanoma</searchLink><br /><searchLink fieldCode="DE" term="%22Prognosis%22">Prognosis</searchLink><br /><searchLink fieldCode="DE" term="%22Markov+Chains%22">Markov Chains</searchLink><br /><searchLink fieldCode="DE" term="%22Treatment+Outcome%22">Treatment Outcome</searchLink><br /><searchLink fieldCode="DE" term="%22Mutation%22">Mutation</searchLink><br /><searchLink fieldCode="DE" term="%22SURVIVAL%22">SURVIVAL</searchLink><br /><searchLink fieldCode="DE" term="%22Disease+Progression%22">Disease Progression</searchLink><br /><searchLink fieldCode="DE" term="%22decision+model%22">decision model</searchLink><br /><searchLink fieldCode="DE" term="%22semi-Markov%22">semi-Markov</searchLink><br /><searchLink fieldCode="DE" term="%22REAL-WORLD%22">REAL-WORLD</searchLink>
– Name: Abstract
  Label: Description
  Group: Ab
  Data: Background A decision model for patients with advanced melanoma to estimate outcomes of a wide range of treatment sequences is lacking. Objectives To develop a decision model for advanced melanoma to estimate outcomes of treatment sequences in clinical practice with the aim of supporting decision making. The article focuses on methodology and long-term health benefits. Methods A semi-Markov model with a lifetime horizon was developed. Transitions describing disease progression, time to next treatment, and mortality were estimated from real-world data (RWD) as a function of time since starting treatment or disease progression and patient characteristics. Transitions were estimated separately for melanoma with and without a BRAF mutation and for patients with favorable and intermediate prognostic factors. All transitions can be adjusted using relative effectiveness of treatments derived from a network meta-analysis of randomized controlled trials (RCTs). The duration of treatment effect can be adjusted to obtain outcomes under different assumptions. Results The model distinguishes 3 lines of systemic treatment for melanoma with a BRAF mutation and 2 lines of systemic treatment for melanoma without a BRAF mutation. Life expectancy ranged from 7.8 to 12.0 years in patients with favorable prognostic factors and from 5.1 to 8.7 years in patients with intermediate prognostic factors when treated with sequences consisting of targeted therapies and immunotherapies. Scenario analyses illustrate how estimates of life expectancy depend on the duration of treatment effect. Conclusion The model is flexible because it can accommodate different treatments and treatment sequences, and the duration of treatment effects and the transitions influenced by treatment can be adjusted. We show how using RWD and data from RCTs can harness advantages of both data sources, guiding the development of future decision models. Highlights The model is flexible because it can accommodate different treatments and treatment sequences, and the duration of treatment effects as well as the transitions that are influenced by treatment can be adjusted. The long-term health benefits of treatment sequences depend on the place of different therapies within a treatment sequence. Assumptions about the duration of relative treatment effects influence the estimates of long-term health benefits. We show how the use of real-world data and data from randomized controlled trials harness the advantages of both data sources, guiding the development of future decision models.
– Name: TypeDocument
  Label: Document Type
  Group: TypDoc
  Data: Article<br />Other literature type
– Name: Format
  Label: File Description
  Group: SrcInfo
  Data: application/pdf
– Name: Language
  Label: Language
  Group: Lang
  Data: English
– Name: ISSN
  Label: ISSN
  Group: ISSN
  Data: 1552-681X<br />0272-989X
– Name: DOI
  Label: DOI
  Group: ID
  Data: 10.1177/0272989x251319338
– Name: URL
  Label: Access URL
  Group: URL
  Data: <link linkTarget="URL" linkTerm="https://pubmed.ncbi.nlm.nih.gov/39985400" linkWindow="_blank">https://pubmed.ncbi.nlm.nih.gov/39985400</link><br /><link linkTarget="URL" linkTerm="https://hdl.handle.net/https://repository.ubn.ru.nl/handle/2066/317779" linkWindow="_blank">https://hdl.handle.net/https://repository.ubn.ru.nl/handle/2066/317779</link><br /><link linkTarget="URL" linkTerm="https://doi.org/10.1177/0272989X251319338" linkWindow="_blank">https://doi.org/10.1177/0272989X251319338</link><br /><link linkTarget="URL" linkTerm="https://pure.eur.nl/en/publications/d251aa20-b9d9-4558-8a6d-1e3132efcf5f" linkWindow="_blank">https://pure.eur.nl/en/publications/d251aa20-b9d9-4558-8a6d-1e3132efcf5f</link><br /><link linkTarget="URL" linkTerm="https://doi.org/10.1177/0272989X251319338" linkWindow="_blank">https://doi.org/10.1177/0272989X251319338</link><br /><link linkTarget="URL" linkTerm="https://research.rug.nl/en/publications/78b43b9d-b315-43b7-860a-00f5bf5a2ef7" linkWindow="_blank">https://research.rug.nl/en/publications/78b43b9d-b315-43b7-860a-00f5bf5a2ef7</link><br /><link linkTarget="URL" linkTerm="https://hdl.handle.net/11370/78b43b9d-b315-43b7-860a-00f5bf5a2ef7" linkWindow="_blank">https://hdl.handle.net/11370/78b43b9d-b315-43b7-860a-00f5bf5a2ef7</link><br /><link linkTarget="URL" linkTerm="https://doi.org/10.1177/0272989X251319338" linkWindow="_blank">https://doi.org/10.1177/0272989X251319338</link><br /><link linkTarget="URL" linkTerm="https://cris.maastrichtuniversity.nl/en/publications/dec7d975-1de4-4147-b028-58c982e4f704" linkWindow="_blank">https://cris.maastrichtuniversity.nl/en/publications/dec7d975-1de4-4147-b028-58c982e4f704</link><br /><link linkTarget="URL" linkTerm="https://doi.org/10.1177/0272989X251319338" linkWindow="_blank">https://doi.org/10.1177/0272989X251319338</link><br /><link linkTarget="URL" linkTerm="https://dspace.library.uu.nl/handle/1874/461022" linkWindow="_blank">https://dspace.library.uu.nl/handle/1874/461022</link><br /><link linkTarget="URL" linkTerm="https://hdl.handle.net/2066/317779" linkWindow="_blank">https://hdl.handle.net/2066/317779</link><br /><link linkTarget="URL" linkTerm="https://repository.ubn.ru.nl//bitstream/handle/2066/317779/317779.pdf" linkWindow="_blank">https://repository.ubn.ru.nl//bitstream/handle/2066/317779/317779.pdf</link>
– Name: Copyright
  Label: Rights
  Group: Cpyrght
  Data: CC BY<br />URL: https://journals.sagepub.com/page/policies/text-and-data-mining-license<br />URL: http://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 License (http://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (http://us.sagepub.com/en-us/nam/open-access-at-sage).
– Name: AN
  Label: Accession Number
  Group: ID
  Data: edsair.doi.dedup.....6f71dc4ba3039165d5644c57bf0e5d3f
PLink https://erproxy.cvtisr.sk/sfx/access?url=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edsair&AN=edsair.doi.dedup.....6f71dc4ba3039165d5644c57bf0e5d3f
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1177/0272989x251319338
    Languages:
      – Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 16
        StartPage: 302
    Subjects:
      – SubjectFull: Proto-Oncogene Proteins B-raf
        Type: general
      – SubjectFull: Decision Support Techniques
        Type: general
      – SubjectFull: COST-EFFECTIVENESS
        Type: general
      – SubjectFull: SDG 3 - Good Health and Well-being
        Type: general
      – SubjectFull: Original Research Articles
        Type: general
      – SubjectFull: Proto-Oncogene Proteins B-raf/genetics
        Type: general
      – SubjectFull: Journal Article
        Type: general
      – SubjectFull: BRAF plus MEK inhibitors
        Type: general
      – SubjectFull: METASTATIC MELANOMA
        Type: general
      – SubjectFull: Humans
        Type: general
      – SubjectFull: Melanoma/drug therapy
        Type: general
      – SubjectFull: Skin Neoplasms/mortality
        Type: general
      – SubjectFull: Medical Oncology - Radboud University Medical Center
        Type: general
      – SubjectFull: Melanoma
        Type: general
      – SubjectFull: treatment sequences
        Type: general
      – SubjectFull: immunotherapies
        Type: general
      – SubjectFull: Advanced melanoma
        Type: general
      – SubjectFull: Prognosis
        Type: general
      – SubjectFull: Markov Chains
        Type: general
      – SubjectFull: Treatment Outcome
        Type: general
      – SubjectFull: Mutation
        Type: general
      – SubjectFull: SURVIVAL
        Type: general
      – SubjectFull: Disease Progression
        Type: general
      – SubjectFull: decision model
        Type: general
      – SubjectFull: semi-Markov
        Type: general
      – SubjectFull: REAL-WORLD
        Type: general
    Titles:
      – TitleFull: Development of a Decision Model to Estimate the Outcomes of Treatment Sequences in Advanced Melanoma
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Saskia de Groot
      – PersonEntity:
          Name:
            NameFull: Hedwig M. Blommestein
      – PersonEntity:
          Name:
            NameFull: Brenda Leeneman
      – PersonEntity:
          Name:
            NameFull: Carin A. Uyl-de Groot
      – PersonEntity:
          Name:
            NameFull: John B. A. G. Haanen
      – PersonEntity:
          Name:
            NameFull: Michel W. J. M. Wouters
      – PersonEntity:
          Name:
            NameFull: Maureen J. B. Aarts
      – PersonEntity:
          Name:
            NameFull: Franchette W. P. J. van den Berkmortel
      – PersonEntity:
          Name:
            NameFull: Willeke A. M. Blokx
      – PersonEntity:
          Name:
            NameFull: Marye J. Boers-Sonderen
      – PersonEntity:
          Name:
            NameFull: Alfons J. M. van den Eertwegh
      – PersonEntity:
          Name:
            NameFull: Jan Willem B. de Groot
      – PersonEntity:
          Name:
            NameFull: Geke A. P. Hospers
      – PersonEntity:
          Name:
            NameFull: Ellen Kapiteijn
      – PersonEntity:
          Name:
            NameFull: Olivier J. van Not
      – PersonEntity:
          Name:
            NameFull: Astrid A. M. van der Veldt
      – PersonEntity:
          Name:
            NameFull: Karijn P. M. Suijkerbuijk
      – PersonEntity:
          Name:
            NameFull: Pieter H. M. van Baal
      – PersonEntity:
          Name:
            NameFull: Pathologie Pathologen staf
      – PersonEntity:
          Name:
            NameFull: Cancer
      – PersonEntity:
          Name:
            NameFull: MS Medische Oncologie
      – PersonEntity:
          Name:
            NameFull: Infection & Immunity
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 22
              M: 02
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 1552681X
            – Type: issn-print
              Value: 0272989X
            – Type: issn-locals
              Value: edsair
            – Type: issn-locals
              Value: edsairFT
          Numbering:
            – Type: volume
              Value: 45
          Titles:
            – TitleFull: Medical Decision Making
              Type: main
ResultId 1